MyoKardia Presents 36-week Data from PIONEER-OLE Study of Mavacamten at the European Society of Cardiology Congress 2019
August 31, 2019 05:00 ET
|
MyoKardia, Inc.
Durability of Mavacamten's Safety and Efficacy Profile Demonstrated through Nine Months in this Study of Patients with Symptomatic, Obstructive HCM Statistically Significant Changes in Key Biomarkers...
MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece
May 28, 2019 08:30 ET
|
MyoKardia, Inc.
First-in-Human Data for MYK-491 in Healthy Volunteers Demonstrated Well-Tolerated Increases in Cardiac Contractility Topline Results from Phase 2a Clinical Trial of MYK-491 in Patients with Stable...
New Insights on Disease Burden for Hypertrophic Cardiomyopathy Patients Published in Circulation
August 23, 2018 08:00 ET
|
MyoKardia, Inc.
HCM Patients at Greater Risks of Atrial Fibrillation, Heart Failure and Increased Mortality Younger Age of Diagnosis and Genetic Status Associated with Higher Rates of Long-term Complications and...